E
Elevian
Developing new medicines to restore regenerative capacity, with the potential to prevent and treat many age-related diseases
About Elevian
Elevian is a biotechnology company focused on developing innovative treatments for stroke recovery. The company operates in the healthcare and pharmaceutical markets, targeting patients who have suffered from ischemic or hemorrhagic strokes. Elevian's lead product, rGDF11, is a recombinant protein designed to promote recovery of motor function by stimulating new blood vessel and neuron formation, as well as reducing inflammation. This approach addresses a significant gap in current stroke treatments, which are limited to the immediate hours following a stroke and do not promote long-term recovery. Elevian's business model involves conducting extensive research and clinical trials to bring rGDF11 to market, aiming to collaborate with healthcare providers and pharmaceutical companies for distribution and commercialization. Revenue is generated through product sales, licensing agreements, and potential partnerships with larger pharmaceutical firms.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Newton, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 70.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2021 | $40M | $160M | Bold Capital Partners · Caleb Bell · Leslie Ventures · John A Kuelbs Family Office | — |
| EARLY VCOther financing | Nov 2020 | $15M | $60M | Kizoo · Longevity Fund · Western Technology Investment · Lauder Partners | — |
Growth signals
Latest recorded traffic for Elevian is 1.5K monthly website visits, up 0% over the last three months. Elevian's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Bold Capital Partners
Kizoo
Longevity Fund
Western Technology Investment
Lauder Partners
For Good Ventures
Prime Movers Lab- SASAVEarth
- CBCaleb Bell
- LVLeslie Ventures
- JOJohn A Kuelbs Family Office
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Elevian on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Elevian’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.